The release and absorption profile of an oral medication is influenced by the
physicochemical properties of the drug and its formulation, as well as by the anatomy and …

Abstract In 1979, the late Dr. Darrell R. Abernethy and colleagues began a series of clinical
studies aimed at understanding the pertinent determinants of drug distribution, elimination …

Aims For a given passively‐distributed lipophilic drug, the extent of in vivo distribution
(pharmacokinetic volume of distribution, Vd) in obese individuals increases in relation to the …

Purpose/Background: Major depressive disorder (MDD) and obesity commonly co-occur.
We sought to assess the impact of body mass index (BMI) on the acute antidepressant …

Background: Changes in the gastrointestinal physiology after bariatric surgery may affect the
pharmacokinetics of medications. Data on the impact of different surgical techniques on the …

Abstract Purpose of Review To provide examples of knowledge gaps in current
pharmaceutical treatments for people with obesity and call for changes to regulatory and …

Purpose/Background: The antipsychotic agent lurasidone (Latuda®) is metabolized by
Cytochrome P450-3A (CYP3A) enzymes. Coadministration with strong CYP3A inhibitors …

Obesity is a serious condition with many known comorbid conditions and other health risks.
Despite the rising global rates of obesity, drug disposition in this population is typically …

Dual‐energy x‐ray absorptiometry (DXA) scanning is used for objective determination of
body composition, but instrumentation is expensive and not generally available in customary …

Depressive symptoms are a customary finding in hospitalized patients, particularly those
who are undergoing long hospitalizations, underwent major surgical procedures or suffer …